Terms: = Prostate cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Clinical Outcome
11 results:
1. A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome.
Ashcraft KA; Johnson-Pais TL; Troyer DA; Hernandez J; Leach RJ
Urol Oncol; 2020 Dec; 38(12):932.e1-932.e7. PubMed ID: 32665124
[TBL] [Abstract] [Full Text] [Related]
2. Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis.
da Costa IA; Hennenlotter J; Stühler V; Kühs U; Scharpf M; Todenhöfer T; Stenzl A; Bedke J
Urol Oncol; 2018 Oct; 36(10):472.e21-472.e27. PubMed ID: 30119993
[TBL] [Abstract] [Full Text] [Related]
3. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression.
Li S; Ma Y; Xie C; Wu Z; Kang Z; Fang Z; Su B; Guan M
Oncotarget; 2015 Sep; 6(26):22587-97. PubMed ID: 26041887
[TBL] [Abstract] [Full Text] [Related]
4. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.
Shirotake S; Miyajima A; Kosaka T; Tanaka N; Kikuchi E; Mikami S; Okada Y; Oya M
Am J Pathol; 2012 Mar; 180(3):1008-1016. PubMed ID: 22226738
[TBL] [Abstract] [Full Text] [Related]
6. TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence.
Zhang Q; Chen L; Helfand BT; Jang TL; Sharma V; Kozlowski J; Kuzel TM; Zhu LJ; Yang XJ; Javonovic B; Guo Y; Lonning S; Harper J; Teicher BA; Brendler C; Yu N; Catalona WJ; Lee C
PLoS One; 2011; 6(9):e25168. PubMed ID: 21980391
[TBL] [Abstract] [Full Text] [Related]
7. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
[TBL] [Abstract] [Full Text] [Related]
8. Anterior perirectal fat tissue thickness is a strong predictor of recurrence after high-intensity focused ultrasound for prostate cancer.
Sumitomo M; Asakuma J; Yoshii H; Sato A; Horiguchi A; Ito K; Nagakura K; Asano T
Int J Urol; 2010 Sep; 17(9):776-82. PubMed ID: 20569272
[TBL] [Abstract] [Full Text] [Related]
9. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.
Gust KM; Hofer MD; Perner SR; Kim R; Chinnaiyan AM; Varambally S; Moller P; Rinnab L; Rubin MA; Greiner J; Schmitt M; Kuefer R; Ringhoffer M
Neoplasia; 2009 Sep; 11(9):956-63. PubMed ID: 19724689
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
Grande M; Carlström K; Rozell BL; Stege R; Pousette A
Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
[TBL] [Abstract] [Full Text] [Related]
11. Tissue PSA is the best predicting variable for the outcome of endocrine treatment of prostatic carcinoma.
Pousette A; Grande M; Carlström K; Stege R
Scand J Clin Lab Invest Suppl; 1999; 229():27-32. PubMed ID: 10097287
[TBL] [Abstract] [Full Text] [Related]
